Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a national ...

Hims & Hers Health, Inc. (HIMS) closed at $58.68 in the latest trading session, marking a +1.79% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw an increase of 0.33%. The stock of company has risen by 16.68% in the past month, leading the Medical sector's gain of 1.92% and the S&P 500's gain of 4.93%.The investment community will be closely monitoring the performance of Hi ...

PHILADELPHIA, July 28, 2025 (GLOBE NEWSWIRE) -- Berger Montague, a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). The firm is examining whether Hims & Hers, during the Class Period from April 29, 2025 through June 22, 2025 (the “Class Period”), violated federal securities laws by making false or misleading statements to investors. Details of the Securities Fraud InvestigationOn June 23 ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hims & Hers Health, Inc. ("Hims & Hers Health" or the "Company") (NYSE: HIMS) investors of a class action representing investors that bought securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"). Hims & Hers Health investors have until August 25, 2025 to file a lead plaintiff motion. Investors are encouraged to con ...

RADNOR, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is Augus ...

SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. The cases seeks to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The lawsuits follow an announcement by Novo Nordisk, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated i ...

虚拟医疗行业概况 - 虚拟医疗行业快速发展 主要参与者包括Hims & Hers Health Inc (HIMS)和Teladoc Health Inc (TDOC) [1] - HIMS采用消费者导向的订阅模式 提供性健康、心理健康、皮肤科和减肥等个性化治疗方案 [1] - Teladoc Health是全球虚拟医疗领导者 提供初级护理、慢性病管理和心理健康等综合服务 2024年访问量超过1700万次 [1] 公司商业模式对比 - HIMS通过垂直整合强调可负担性和个性化服务 [2] - Teladoc Health注重广泛的临床覆盖和企业合作关系 [2] - HIMS平台整合了远程医疗咨询、诊断和药房配送服务 形成一站式数字解决方案 [7] - Teladoc Health的BetterHelp平台拥有超过35000名持证临床医生 提供灵活的心理健康服务 [10] 股票表现与估值 - 过去三个月HIMS股价上涨64.5% 同期TDOC上涨11.9% [3] - 过去一年HIMS股价飙升165.6% 而TDOC下跌14.3% [3][6] - HIMS远期市销率为4.89倍 高于三年中位数2.34倍 [5] - TDOC远期市销率为0.57倍 低于三年中位数1.02倍 [5] 公司发展战略 - HIMS通过收购ZAVA加速欧洲扩张 获得130万客户 并计划2026年进入加拿大市场 [6][8] - HIMS任命AI专家Mo Elshenawy为首席技术官 投资8700万美元可转换票据发展AI基础设施 [9] - Teladoc Health通过Primary360和Chronic Care Complete等解决方案满足复杂临床需求 [11] - Teladoc Health的国际业务覆盖9000万会员 医院电视虚拟护理终端提升服务效率 [12] 财务指标与预测 - HIMS 2025年第一季度订阅用户达240万 同比增长38.4% [7] - Teladoc Health的BetterHelp平台2025年第一季度收入下降10.8% 付费用户减少4% [10] - HIMS 2025年每股收益预计为0.75美元 2026年预计增长至1.03美元 [15] - Teladoc Health 2025年每股亏损预计改善79.4% [16] 分析师评级与目标价 - 12位分析师给出的HIMS平均目标价为47.67美元 较当前价格有17.3%下行空间 [18] - 20位分析师给出的TDOC平均目标价为9.26美元 较当前价格有12.9%上行空间 [19] - HIMS获得Zacks"强力买入"评级(1级) TDOC为"持有"评级(3级) [20][23]

Hims & Hers Health, Inc. (HIMS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

SAN DIEGO, July 28, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certa ...